| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 38.57% | 91.90% | 91.90% | 91.90% | — | -330.38% | 32.49% | — | — | — | — | — |
| Operating Margin | -5936.95% | -6526.44% | -5347.41% | -5031.28% | — | -6287.34% | -2293.38% | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | -5863.50% | -6092.59% | -5132.57% | -5420.86% | — | -7422.52% | -2497.71% | — | — | — | — | — |
| Current Ratio | 11.36 | 4.29 | 9.90 | 26.52 | 21.23 | 10.07 | 4.23 | 13.05 | 42.81 | — | 0.01 | 0.50 |
| Quick Ratio | 11.36 | 4.29 | 9.90 | 26.52 | 21.23 | 9.83 | 2.89 | 12.49 | 42.81 | — | 0.01 | 0.50 |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE | -67.05% | -87.26% | -59.91% | -37.80% | 43.08% | -237.18% | 4426.41% | -237.94% | 29.64% | — | 95.76% | 2849.14% |
| ROA | -55.59% | -59.27% | -47.77% | -33.57% | 37.21% | -212.91% | -205.18% | -113.33% | 21.72% | — | -14138.35% | -2842.64% |
| Asset Turnover | 0.01 | 0.01 | 0.01 | 0.01 | — | 0.03 | 0.08 | — | — | — | — | — |
| Book Value / Share | 0.75 | 1.37 | 2.01 | 4.53 | 0.09 | 0.02 | -0.00 | 0.01 | 0.02 | — | -0.00 | -0.00 |
Silo Pharma Inc. is a developmental stage biopharmaceutical company focused on developing novel therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, chronic pain, and central nervous system diseases such as Alzheimer's and multiple sclerosis. The company merges traditional therapies with psychedelic medicine, utilizing innovative formulations and drug delivery systems like intranasal treatments and time-release implants. Its lead program, SPC-15, is an intranasal formulation targeting PTSD and stress-induced anxiety. SP-26 is a ketamine-based injectable dissolvable implant designed for fibromyalgia and chronic pain relief. Preclinical efforts include SPC-14, an intranasal compound for Alzheimer's disease, and SPU-16, a CNS-homing peptide for multiple sclerosis. Silo Pharma acquires intellectual property from universities and researchers, pursuing streamlined clinical pathways. Founded in 2010 and headquartered in Sarasota, Florida, the company partners with leading academic institutions to advance its pipeline of psychedelic and conventional treatments for psychiatric and neurological disorders.